Evidence map›Paper›PMID 40353951›Full record

ArticlePhysical and engineering sciences in medicine2025

Exploring the dosimetric advantages of a novel multi-modality radiotherapy platform in prostate cancer.

Jie Duan, Qinghui Yun, Zhongfei Wang, Te Zhang, Xiaohuan Sun, Hua Yang, Weiwei Li, Wei Wang, Hongfei Sun, Liting Chen and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Physical and engineering sciences in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jie Duan *Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Qinghui Yun *Department of Equipment, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Zhongfei Wang *Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Te ZhangDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Xiaohuan SunDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Hua YangDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Weiwei LiDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Wei WangDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Hongfei SunDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Liting ChenDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Yue GaoDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Zhiwei WeiOur United Corp, Xi'an, 710032, China.
Zhe WangDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. wangzhe9263@163.com.
Lina ZhaoDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. zhaolina@fmmu.edu.cn.ORCID https://orcid.org/0000-0002-0011-6471

Funding

National Key R&D Program of China 2023YFC2413903
6 · The paper itself

Abstract

The present research aims to explore the dosimetric advantages associated with a novel multi-modality radiotherapy platform TaiChiB, which integrates a medical linac and a focused

Indexed as

Prostatic NeoplasmsRadiometryCombined Modality TherapyHumansMaleRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRetrospective StudiesDosimetric advantagesFocused gamma-ray systemLinacMulti-modalityProstate cancer

Identifiers

PMID40353951

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.